论文部分内容阅读
目的 :研究nm2 3、p2 1ras癌基因、VEGF和ER在乳腺癌组织中的表达及与临床预后的关系。方法 :随机选择 1988～ 1995年在本院手术的乳腺癌患者 86例 ,乳腺良性病变患者 2 8例。检测方法采用免疫组化法 (S P法 )。免疫组化检测结果结合术后长期随访资料进行分析。结果 :nm2 3、p2 1ras、VEGF、ER在乳腺癌阳性表达分别为 77 9%、87 2 %、86 0 %、6 8 6 % ,明显高于良性病变组 (p <0 0 5)。ER阳性表达率在乳腺癌临床分期Ⅰ～Ⅱ期高于Ⅲ～Ⅳ期 (P <0 0 5)。nm2 3阳性患者术后生存率高于nm2 3阴性者 ,ER阳性患者术后生存率高于ER阴性者 ,VEGF阴性患者术后生存率高于VEGF阳性者 (P <0 0 5)。p2 1ras与术后生存率无明显关系 (P >0 0 5)。结论 :乳腺癌的nm2 3、p2 1ras、VEGF和ER阳性表达率明显高于良性病变。nm2 3、ER阳性 ,VEGF阴性的乳腺癌预后较好。nm2 3及ER、VEGF可以作为乳腺癌的预后指标 ,有较大的临床意义。
Objective : To study the expression of nm23, p21ras oncogene, VEGF and ER in breast cancer and their relationship with clinical prognosis. Methods: 86 patients with breast cancer who underwent surgery in our hospital from 1988 to 1995 and 28 patients with benign breast disease were randomly selected. The detection method used immunohistochemistry (S P method). Immunohistochemical results were combined with postoperative long-term follow-up data for analysis. RESULTS: The positive expressions of nm23, p21ras, VEGF, and ER in breast cancer were 77.9%, 87.6%, 86.0%, and 6.86%, respectively, which were significantly higher than those in benign lesions (p<0.05). The positive expression rate of ER was higher in stages I-II of breast cancer than in stages III-IV (P < 0.05). The survival rate of nm23-positive patients was higher than that of nm23-negative patients. The survival rate of ER-positive patients was higher than that of ER-negative patients. The survival rate of VEGF-negative patients was higher than that of VEGF-positive patients (P < 0.05). There was no significant relationship between p2 1ras and postoperative survival (P > 0 05). Conclusion :The positive rates of nm23, p21ras, VEGF and ER in breast cancer were significantly higher than those in benign lesions. Nm2 3, ER positive, VEGF negative breast cancer prognosis is better. Nm23, ER, and VEGF can be used as prognostic indicators of breast cancer and have greater clinical significance.